GPR65 and neoplasm: However, a notable in vitro study validated a series of four novel GPR65 antagonists (SD2571, SD2593, SD2594, and SD2758) that were able enhance anti-tumour T-cell function and cytokine production in an acidic co-culture of immune cells and tumour cells.